NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
“We plan on leveraging our PATrOL™ platform to perform ‘nuclease free’ in vivo gene editing to restore healthy gene function.
- “We plan on leveraging our PATrOL™ platform to perform ‘nuclease free’ in vivo gene editing to restore healthy gene function.
- This technology complements the field of CRISPR/Cas editors, base editors, and prime editors, with the potential to address the majority of disease-causing mutations.
- We believe the high fidelity and lack of immunogenicity of our editing approach offer the possibility to address tissue turnover by redosing.
- Throughout calendar year 2023, we anticipate sharing data on ex vivo and in vivo editing results against high-value genetic mutations, together with associated performance metrics, such as fidelity and efficiency.